# HROW — Harrow Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** HROW  
**Sources:** 17  
**Published:** 2026-09-16  
**Canonical:** https://app.k3vl4r.com/research/deep-research-hrow-harrow-inc-catalysts-narrative-risks-3961

---

## Company Snapshot

Harrow, Inc. (Nasdaq: HROW) is a leading North American provider of ophthalmic disease management solutions, with a portfolio covering conditions affecting both the front and back of the eye (dry eye disease, wet/neovascular AMD, cataracts, refractive errors, glaucoma, and retinal diseases) [[3]](https://www.marketscreener.com/news/harrow-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-september-30-2026-ce785edad988f42d), [[5]](https://markets.businessinsider.com/news/stocks/harrow-to-report-third-quarter-2026-financial-results-after-market-close-on-november-9-2026-1036665087). It operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business [[10]](https://tickernerd.com/stock/hrow-forecast/). (Note: some aggregators render the name as "Harrow Health, Inc.") [[11]](https://tickflow.io/stock/HROW/forecast). The data types relevant to covering this stock—press releases, analyst opinions, earnings transcripts, and price data—are exactly the unstructured and structured inputs that modern equity-analysis frameworks draw upon [LIB-1], [LIB-2].

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-hrow-harrow-inc-catalysts-narrative-risks-3961 (free to sign up)._
